BOSTON–Leena Dang Dalal, 51, a respected biotechnology and pharmaceutical executive, passed away suddenly on Friday, February 6, 2026.
She is survived by her husband, Sandeep Dalal; her daughters, Sophia and Julia; her parents, Binita and Harish Dang; her mother-in-law, Chitra Dalal; and her brothers, Amit and Neil, along with their families.
A private service will be held this week for family only, with plans for a memorial service in the spring to be shared at a later date.
Ms. Dalal was a devoted daughter, wife, mother, sister, and friend whose kindness, warmth, and generosity of spirit left a lasting impression on everyone she met. She was known for her ability to make others feel seen and supported, and her presence brought light and steadiness to both her personal and professional communities.
She will be remembered for her compassion, her radiant smile, and the love she shared so freely. Her spirit will live on through the many lives she touched and the memories she created.
Over a career spanning more than 25 years, Ms. Dalal built a distinguished reputation as a strategic commercial leader in the biotechnology and pharmaceutical industries. She held senior leadership roles at uniQure, Alnylam Pharmaceuticals, and Vertex Pharmaceuticals, where she led commercialization, marketing, and brand organizations for high-science therapies from early clinical development through U.S. and global launch.
Her experience spanned rare and specialty diseases, neurology, cardiology, and gene therapy. She contributed to industry-recognized launches including ONPATTRO and INCIVEK and most recently led the integrated launch strategy for uniQure’s AMT-130, an investigational, first-in-class disease-modifying therapy for Huntington’s disease.
She was widely respected for her ability to translate complex scientific concepts into clear, differentiated commercial strategies and for building high-performing, cross-functional teams during periods of growth and change.
Ms. Dalal’s leadership and impact were recognized with multiple honors, including three CEO Awards from Alnylam and the Vertex Outstanding Contribution Award. Her work helped advance innovative therapies for patients with serious and rare diseases, leaving a legacy that extends well beyond her immediate field.
